# OnCo record head-and-neck (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/head-and-neck/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "head-and-neck" ;
  schema:name "Head and neck squamous cell carcinoma"@en ;
  schema:alternateName "HNSC"@en, "HNSCC"@en, "TCGA-HNSC"@en, "head and neck squamous cell carcinoma (TCGA HNSC cohort)"@en ;
  schema:description "Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."@en ;
  schema:url <https://onco.cc/cancers/head-and-neck/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Head_and_neck_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1783924> ;
  schema:citation <https://en.wikipedia.org/wiki/Head_and_neck_cancer> ;
  onco:tag "head-neck", "spike" ;
  onco:related <https://onco.cc/pairings/io-before-surgery-hnscc/>, <https://onco.cc/pairings/egfr-bispecific-plus-pd1-hnscc/>, <https://onco.cc/pairings/hpv-deescalation-caution/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/photoimmunotherapy/>, <https://onco.cc/technologies/bnct/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/hpv-vaccine/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/acupuncture-xerostomia/>, <https://onco.cc/technologies/glutamine-mucositis-neuropathy/>, <https://onco.cc/technologies/honey-radiation-mucositis/>, <https://onco.cc/technologies/hyperbaric-oxygen-radiation-injury/>, <https://onco.cc/technologies/tors/>, <https://onco.cc/technologies/cthpv-dna/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sentinel-node/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/terms/lgr5/> ;
  onco:drugs <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/petosemtamab/>, <https://onco.cc/drugs/ficerafusp-alfa/>, <https://onco.cc/drugs/cetuximab-sarotalocan/>, <https://onco.cc/drugs/amifostine/>, <https://onco.cc/drugs/temoporfin/> ;
  onco:companies <https://onco.cc/companies/epicentrx/>, <https://onco.cc/companies/neonc-technologies/>, <https://onco.cc/companies/rakuten-medical/>, <https://onco.cc/companies/ap-biosciences/>, <https://onco.cc/companies/aveta-biomics/>, <https://onco.cc/companies/qbiotics/>, <https://onco.cc/companies/scancell/>, <https://onco.cc/companies/tiumbio/>, <https://onco.cc/companies/vyriad/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/merus/>, <https://onco.cc/companies/genmab/>, <https://onco.cc/companies/debiopharm/>, <https://onco.cc/companies/intuitive-surgical/>, <https://onco.cc/companies/nrg-oncology/> ;
  onco:institutions <https://onco.cc/institutions/sysucc/>, <https://onco.cc/institutions/tata-memorial/>, <https://onco.cc/institutions/dana-farber/> ;
  onco:terms <https://onco.cc/terms/hpv-p16/>, <https://onco.cc/terms/lgr5/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:trials <https://onco.cc/trials/nct06082167/>, <https://onco.cc/trials/nct06601335/>, <https://onco.cc/trials/nct04590963/>, <https://onco.cc/trials/nct05751512/>, <https://onco.cc/trials/nct06295731/>, <https://onco.cc/trials/nct04892173/>, <https://onco.cc/trials/nct04534205/>, <https://onco.cc/trials/nct06064877/>, <https://onco.cc/trials/nct06699212/>, <https://onco.cc/trials/nct06496178/>, <https://onco.cc/trials/nct03769506/>, <https://onco.cc/trials/nct06256588/>, <https://onco.cc/trials/nct07276399/>, <https://onco.cc/trials/nct05893888/>, <https://onco.cc/trials/keynote-048/>, <https://onco.cc/trials/keynote-689/>, <https://onco.cc/trials/extreme/>, <https://onco.cc/trials/checkmate-141/>, <https://onco.cc/trials/rtog-0129/>, <https://onco.cc/trials/nrg-hn002-hn005/>, <https://onco.cc/trials/javelin-hn-100/>, <https://onco.cc/trials/trilynx/>, <https://onco.cc/trials/jupiter-02/>, <https://onco.cc/trials/liger-hn1/>, <https://onco.cc/trials/fortifi-hn01/> ;
  onco:journals <https://onco.cc/journals/head-and-neck-journal/>, <https://onco.cc/journals/head-and-neck-pathology/>, <https://onco.cc/journals/oral-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/tilatamig-samrotecan/>, <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/drugs/shr-a2102/>, <https://onco.cc/drugs/domvanalimab/>, <https://onco.cc/drugs/si-b001/>, <https://onco.cc/drugs/hs-20093/>, <https://onco.cc/drugs/zanzalintinib/>, <https://onco.cc/drugs/ak117/>, <https://onco.cc/drugs/monalizumab/>, <https://onco.cc/drugs/sys6010/>, <https://onco.cc/drugs/mrg003/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/io102-io103/>, <https://onco.cc/drugs/inbrx-106/>, <https://onco.cc/drugs/jnj-90301900/>, <https://onco.cc/drugs/bnt113/>, <https://onco.cc/drugs/ficlatuzumab/>, <https://onco.cc/drugs/t3011/>, <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/hmbd-001/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/lvgn6051/>, <https://onco.cc/drugs/avasopasem-manganese/>, <https://onco.cc/drugs/petosemtamab/>, <https://onco.cc/trials/liger-hn1/>, <https://onco.cc/drugs/ficerafusp-alfa/>, <https://onco.cc/trials/fortifi-hn01/>, <https://onco.cc/drugs/cetuximab-sarotalocan/>, <https://onco.cc/technologies/cthpv-dna/>, <https://onco.cc/ideas/idea-cthpv-adapted-deescalation/>, <https://onco.cc/ideas/idea-photoimmunotherapy-plus-pd1/>, <https://onco.cc/pairings/egfr-bispecific-plus-pd1-hnscc/>, <https://onco.cc/technologies/bnct/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/targets/b7h3/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/photoimmunotherapy/>, <https://onco.cc/technologies/hpv-vaccine/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/tors/>, <https://onco.cc/trials/nrg-hn002-hn005/>, <https://onco.cc/pairings/hpv-deescalation-caution/>, <https://onco.cc/trials/rtog-0129/>, <https://onco.cc/trials/keynote-689/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/pairings/io-before-surgery-hnscc/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/javelin-hn-100/>, <https://onco.cc/trials/trilynx/>, <https://onco.cc/trials/keynote-048/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/extreme/>, <https://onco.cc/trials/checkmate-141/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/liger-hn1/>, <https://onco.cc/trials/fortifi-hn01/>, <https://onco.cc/drugs/cetuximab-sarotalocan/>, <https://onco.cc/technologies/photoimmunotherapy/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/bnct/>, <https://onco.cc/trials/jupiter-02/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/fronts/supportive-care/> .